Abstract
Objective: To evaluate the clinical value of serum tumor supplied group of factor (TSGF) in diagnosis of epithelial ovarian cancer. Methods: The serum TSGF was tested in 69 patients with epithelial ovarian cancer, 28 patients with benign ovarian lesion and 61 healthy women. The serum levels of vascular endothelial growth factor (VEGF) and CA125 were determined in patients with epithelial ovarian cancer and in those with benign ovarian lesion. The correlations of TSGF with VEGF and CA125 were investigated. Results: The serum level of TSGF in patients with epithelial ovarian cancer was obviously higher than in patients with benign ovarian lesion and in healthy women (P<0.01). The serum level of TSGF in patients with epithelial cancer was associated with stage and grade. TSGF was highest in stage III, followed by stage IV, and was lowest in stage I-II. The TSGF level was lower in well-differentiated tumors and was higher in poorly differentiated tumor. There were no significant difference among diagnostic value of TSGF, VEGF, and CA125 in differentiation between epithelial ovarian cancer and benign ovarian lesion (P>0.05). The serum level of TSGF and VEGF and CA125 in patients with epithelial ovarian cancer showed positive correlation (P<0.01, P<0.05, respectively). Conclusion: There is no marked difference in diagnostic value among TSGF, VEGF and CA125. TSGF has a certain value in diagnosis of epithelial ovarian cancer, and is helpful to distinguish epithelial ovarian cancer from benign ovarian lesion.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Zeng XI, Mai XX, Li XA. A new tumor marker—tumor specific growth factor (TSGF) in patients with malignant tumors [J]. Int J Med Cancer Ther 2000; 3:20.
Ye M. Introduction of an earlier diagnosing method [J] (in Chinese). Fujian J Med Lab Sci 1996; 1:31.
Gao WB, Qi XJ, Yi SZ. Clinical significance of serum tumor specific growth factor in intervening treatment of hepatic cancer [J] (in Chinese). Shanghai J Immunol 1998; 18:126.
Lao M, Huang LS. Application of TSGF in diagnosis and therapeutic investigation of tumor [J] (in Chinese). Anthol Med 1999; 18:8.
Xu YB, Wang CD, Zhu ZY. The assay of tumor specific growth factor (TSGF) and its clinical applications [J] (in Chinese). Fujian J Med Lab Sci 1996; 1:118.
Zhang ML, Xin XB, Fan LY. The assay and clinical significance of serum tumor specific growth factor in patients with malignant diseases [J] (in Chinese). Med J Qilu 2000; 15:23.
Zu B, Huang DR, Huang WC. Analysis to results of serum tumor specific growth factor in patients with benign or malignant tumor [J] (in Chinese). Guangxi Med J 1999; 21:617.
Duan P, Wang HY Monitoring value of CA125 detection for diagnosis and follow-up survey relapse on ovarian epithelial cancer [J] (in Chinese). J Shanghai Med Univ 2000; 27:415.
Song XR, Wang SP, Liu MQ. Significance of serum CA125 in monitoring efficiency and recurrence of advanced ovarian cancer [J] (in Chinese). Mod Diagn Treat 2001; 12:71.
Kraft A, Weindel K, Ochs S, et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease [J]. Cancer 1999; 85:178.
Oehler MK, Caffier H. Diagnostic value of serum VEGF in women with ovarian tumors [J]. Anticancer Res 1999; 19:2519.
Tempfer C, Obermair A, Hefler L, et al. Vascular endothelial growth factor serum concentrations in ovarian cancer [J]. Obester Gynecol 1998; 92:360.
Author information
Authors and Affiliations
Corresponding author
Additional information
Biography: CHENG Qi-hui (1970-), female, attending physician, Hangzhou First People’s Hospital, majors in gynecology.
Rights and permissions
About this article
Cite this article
Cheng, Qh., Zhang, Xp. & Zeng, XI. Clinical value of serum tumor supplied group of factor in diagnosis of epithelial ovarian cancer. Chin J Cancer Res 15, 232–234 (2003). https://doi.org/10.1007/s11670-003-0033-z
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s11670-003-0033-z